KR102189442B1 - 소수성 조성물용 생분해성 약물 전달 - Google Patents

소수성 조성물용 생분해성 약물 전달 Download PDF

Info

Publication number
KR102189442B1
KR102189442B1 KR1020157002309A KR20157002309A KR102189442B1 KR 102189442 B1 KR102189442 B1 KR 102189442B1 KR 1020157002309 A KR1020157002309 A KR 1020157002309A KR 20157002309 A KR20157002309 A KR 20157002309A KR 102189442 B1 KR102189442 B1 KR 102189442B1
Authority
KR
South Korea
Prior art keywords
biodegradable
repeating units
composition
formula
copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157002309A
Other languages
English (en)
Korean (ko)
Other versions
KR20150027265A (ko
Inventor
조르쥬 고드리올
크리스토프 로베르즈
Original Assignee
메딘셀 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49117888&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102189442(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 메딘셀 에스.에이. filed Critical 메딘셀 에스.에이.
Publication of KR20150027265A publication Critical patent/KR20150027265A/ko
Application granted granted Critical
Publication of KR102189442B1 publication Critical patent/KR102189442B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157002309A 2012-06-27 2013-06-27 소수성 조성물용 생분해성 약물 전달 Active KR102189442B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261665192P 2012-06-27 2012-06-27
US61/665,192 2012-06-27
PCT/IB2013/001547 WO2014001904A1 (en) 2012-06-27 2013-06-27 Biodegradable drug delivery for hydrophobic compositions

Publications (2)

Publication Number Publication Date
KR20150027265A KR20150027265A (ko) 2015-03-11
KR102189442B1 true KR102189442B1 (ko) 2020-12-11

Family

ID=49117888

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157002309A Active KR102189442B1 (ko) 2012-06-27 2013-06-27 소수성 조성물용 생분해성 약물 전달

Country Status (23)

Country Link
US (5) US20150150987A1 (enExample)
EP (1) EP2866837B1 (enExample)
JP (1) JP6134788B2 (enExample)
KR (1) KR102189442B1 (enExample)
CN (1) CN104582733B (enExample)
AU (1) AU2013282891B2 (enExample)
BR (1) BR112014031773B1 (enExample)
CA (1) CA2877083C (enExample)
CL (1) CL2014003531A1 (enExample)
CO (1) CO7160098A2 (enExample)
CR (1) CR20140581A (enExample)
CU (1) CU24287B1 (enExample)
EA (1) EA031522B1 (enExample)
ES (1) ES2938586T3 (enExample)
IL (1) IL236472B (enExample)
IN (1) IN2014DN11063A (enExample)
MA (1) MA37809B1 (enExample)
MX (1) MX353280B (enExample)
SG (1) SG11201408658PA (enExample)
TN (1) TN2014000520A1 (enExample)
UA (1) UA113549C2 (enExample)
WO (2) WO2014001905A1 (enExample)
ZA (1) ZA201409291B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
UA119324C2 (uk) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Композиції фармацевтично активних речовин, що містять моноетиловий ефір діетиленгліколю або інші алкільні похідні
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP6640725B2 (ja) 2014-01-27 2020-02-05 セントレ ナショナル デ ラ レチャーチェ シャーティフィック ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016054197A1 (en) * 2014-09-30 2016-04-07 University Of Tennessee Research Foundation In situ gelling form for long-acting drug delivery
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
FR3027522B1 (fr) 2014-10-27 2016-12-09 I Ceram Composition poreuse chargee en principe actif
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2016355236C1 (en) * 2015-11-16 2022-09-22 Medincell A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
US11766400B2 (en) * 2016-10-24 2023-09-26 Yale University Biodegradable contraceptive implants
JP2020511483A (ja) 2017-03-20 2020-04-16 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 徐放性オランザピン製剤
SI3655017T1 (sl) 2017-07-17 2025-06-30 Medincell S.A. Farmacevtski sestavki
GB2568526A (en) 2017-11-20 2019-05-22 Rebio Tech Oy Composition
CN108078911A (zh) * 2017-12-08 2018-05-29 复旦大学 用于动物避孕的热致水凝胶缓释兽药注射剂及其制备方法
JP7482874B2 (ja) * 2018-08-22 2024-05-14 バカイン バイオセラピューティクス， リミテッド シクロスポリン組成物および使用方法
GB201900258D0 (en) * 2019-01-08 2019-02-27 Medincell Pharmaceutical composition
EP4027973B8 (en) 2019-09-13 2025-12-17 Medincell S.A. Drug delivery formulations
CN111700876A (zh) * 2020-03-12 2020-09-25 上海市肿瘤研究所 一种治疗系统性红斑狼疮的载药递送给药系统及其制备方法
WO2022129417A1 (en) 2020-12-16 2022-06-23 Medincell Methods and compositions for the prophylactic treatment of sars-cov-2 virus (covid-19)
FI20215186A1 (en) 2021-02-19 2022-08-20 Rebio Tech Oy Compositions for ophthalmic treatment
AU2022236485A1 (en) 2021-03-17 2023-08-24 Medincell S. A. Long acting injectable formulation comprising risperidone and biodegradable polymers
AU2022264844A1 (en) * 2021-04-30 2023-11-23 Medincell Sa New formulation
WO2025081046A1 (en) * 2023-10-11 2025-04-17 The Brigham And Women's Hospital, Inc. Ultra-high drug loading injectable drug suspension of hydrophobic drugs for long-term drug delivery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112170A1 (en) 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8416234D0 (en) * 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
HU222501B1 (hu) * 1991-06-28 2003-07-28 Endorecherche Inc. MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
KR0180334B1 (ko) * 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
FR2741628B1 (fr) 1995-11-29 1998-02-06 Centre Nat Rech Scient Nouveaux hydrogels a base de copolymeres trisequences et leur application notamment a la liberation progressive de principes actifs
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
WO2002085337A1 (en) 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
CN100408099C (zh) * 2000-11-09 2008-08-06 阿斯特拉曾尼卡有限公司 含有嵌段共聚物的口服药物组合物
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
US6592899B2 (en) 2001-10-03 2003-07-15 Macromed Incorporated PLA/PLGA oligomers combined with block copolymers for enhancing solubility of a drug in water
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
WO2005000278A1 (en) * 2003-06-26 2005-01-06 Mediolanum Pharmaceuticals Ltd. Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
WO2007019439A2 (en) * 2005-08-04 2007-02-15 Angiotech International Ag Block copolymer compositions and uses thereof
CN101273963A (zh) * 2007-11-22 2008-10-01 山东蓝金生物工程有限公司 一种含激素类抗癌药的温控缓释注射剂
US8846068B2 (en) * 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
EP2359860B1 (en) * 2008-11-21 2014-08-06 Samyang Biopharmaceuticals Corporation Polymer micelle composition for treatment of resistant cancer cells
CN101810560B (zh) * 2009-02-20 2013-07-10 北京大学 环孢a聚合物胶束组合物
AU2011350898B2 (en) * 2010-12-29 2016-09-08 Medincell Biodegradable drug delivery compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112170A1 (en) 2003-11-20 2005-05-26 Hossainy Syed F. Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same

Also Published As

Publication number Publication date
SG11201408658PA (en) 2015-02-27
US20220354956A1 (en) 2022-11-10
MA37809B1 (fr) 2018-12-31
AU2013282891A1 (en) 2015-01-22
ZA201409291B (en) 2017-05-31
AU2013282891A2 (en) 2015-02-05
JP2015522001A (ja) 2015-08-03
KR20150027265A (ko) 2015-03-11
MX2014015902A (es) 2015-07-17
HK1208374A1 (en) 2016-03-04
EA031522B1 (ru) 2019-01-31
IL236472A0 (en) 2015-02-26
JP6134788B2 (ja) 2017-05-24
CN104582733B (zh) 2017-07-04
US20190160171A1 (en) 2019-05-30
EP2866837A1 (en) 2015-05-06
TN2014000520A1 (en) 2016-03-30
WO2014001904A1 (en) 2014-01-03
IL236472B (en) 2020-02-27
BR112014031773B1 (pt) 2020-10-13
WO2014001905A1 (en) 2014-01-03
CA2877083C (en) 2020-10-06
EA201492172A1 (ru) 2015-09-30
US20200085958A1 (en) 2020-03-19
CO7160098A2 (es) 2015-01-15
MA37809A1 (fr) 2017-07-31
CN104582733A (zh) 2015-04-29
CA2877083A1 (en) 2014-01-02
EP2866837B1 (en) 2022-12-14
BR112014031773A2 (pt) 2017-06-27
CL2014003531A1 (es) 2015-08-28
UA113549C2 (xx) 2017-02-10
CR20140581A (es) 2015-02-06
US20210008216A1 (en) 2021-01-14
AU2013282891B2 (en) 2018-04-12
CU20140148A7 (es) 2015-03-30
MX353280B (es) 2018-01-05
US20150150987A1 (en) 2015-06-04
IN2014DN11063A (enExample) 2015-09-25
ES2938586T3 (es) 2023-04-12
CU24287B1 (es) 2017-12-08

Similar Documents

Publication Publication Date Title
KR102189442B1 (ko) 소수성 조성물용 생분해성 약물 전달
US20220202942A1 (en) Biodegradable drug delivery compositions
HK1248146A1 (en) Biodegradable drug delivery compositions
HK1248146B (en) Biodegradable drug delivery compositions
HK1190925A (en) Biodegradable drug delivery compositions
HK1190925B (en) Biodegradable drug delivery compositions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150127

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180601

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191106

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200501

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20191106

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200501

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200206

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150130

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200612

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20200909

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20200811

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200603

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200501

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200206

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150130

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201204

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201207

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241119

Start annual number: 5

End annual number: 5